ISG20L2

Across TCGA pan-cancer cohorts, ISG20L2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ISG20L2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ISG20L2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ISG20L2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where ISG20L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.585	0.841	.005	19	view →
CCRCC	OS	Quartile	III,IV	0.256	0.739	.002	13	view →
LSCC	OS	Median	II,III,IV	0.882	0.608	.014	9	view →
PDAC	DFS	Tertile	IV	0.752	0.205	.024	6	view →
LUAD	DFS	Tertile	III,IV	0.962	0.471	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ISG20L2–HNSC (OS)

Open the HNSC breakdown →